Doxorubicin hydrochloride‐loaded electrospun poly(<scp>l</scp>‐lactide‐<i>co</i>‐ε‐caprolactone)/gelatin core–shell nanofibers for controlled drug release

Wang, Lei; Xin, Binjie; Li, Tingxiao

doi:10.1002/pi.6270

Cited by 9 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mixture with vildagliptin decreased the content of PLGA in the composite herein. The maximum elongation and strength at breakage of PLGA nanofibers were reduced accordingly ( Wang et al, 2021a ; Wang et al, 2021b ).…”

Section: Resultsmentioning

confidence: 99%

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing

Lee

Chen

Hsieh

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Introduction: Slow wound repair in diabetes is a serious adverse event that often results in loss of a limb or disability. An advanced and encouraging vehicle is wanted to enhance clinically applicable diabetic wound care. Nanofibrous insulin/vildagliptin core-shell biodegradable poly (lactic-co-glycolic acid) (PLGA) scaffolds to prolong the effective drug delivery of vildagliptin and insulin for the repair of diabetic wounds were prepared.Methods: To fabricate core-shell nanofibrous membranes, vildagliptin mixture with PLGA, and insulin solution were pumped via separate pumps into two differently sized capillary tubes that were coaxially electrospun.Results and Discussion: Nanofibrous core-shell scaffolds slowly released effective vildagliptin and insulin over 2 weeks in vitro migration assay and in vivo wound-healing models. Water contact angle (68.3 ± 8.5° vs. 121.4 ± 2.0°, p = 0.006) and peaked water absorbent capacity (376% ± 9% vs. 283% ± 24%, p = 0.003) of the insulin/vildagliptin core-shell nanofibrous membranes remarkably exceeded those of a control group. The insulin/vildagliptin-loaded core-shell nanofibers improved endothelial progenitor cells migration in vitro (762 ± 77 cells/mm2 vs. 424.4 ± 23 cells/mm2, p < 0.001), reduced the α-smooth muscle actin content in vivo (0.72 ± 0.23 vs. 2.07 ± 0.37, p < 0.001), and increased diabetic would recovery (1.9 ± 0.3 mm2 vs. 8.0 ± 1.4 mm2, p = 0.002). Core-shell insulin/vildagliptin-loaded nanofibers extend the drug delivery of insulin and vildagliptin and accelerate the repair of wounds associated with diabetes.

show abstract

Section: Resultsmentioning

confidence: 99%

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing

Lee

Chen

Hsieh

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Several reported ES DDS containing DOX have been reported for the sustained release of DOX [110,111,115]. The release of DOX from PLA ES DDS has been widely reported with or without nanocarriers, such as graphene oxide and mesoporous silica nanoparticles (MSNs) [17,56].…”

Section: Chemotherapy Drugsmentioning

confidence: 99%

Electrospun Nanofibers: Shaping the Future of Controlled and Responsive Drug Delivery

Wildy,

2023

Materials

View full text Add to dashboard Cite

Electrospun nanofibers for drug delivery systems (DDS) introduce a revolutionary means of administering pharmaceuticals, holding promise for both improved drug efficacy and reduced side effects. These biopolymer nanofiber membranes, distinguished by their high surface area-to-volume ratio, biocompatibility, and biodegradability, are ideally suited for pharmaceutical and biomedical applications. One of their standout attributes is the capability to offer the controlled release of the active pharmaceutical ingredient (API), allowing custom-tailored release profiles to address specific diseases and administration routes. Moreover, stimuli-responsive electrospun DDS can adapt to conditions at the drug target, enhancing the precision and selectivity of drug delivery. Such localized API delivery paves the way for superior therapeutic efficiency while diminishing the risk of side effects and systemic toxicity. Electrospun nanofibers can foster better patient compliance and enhanced clinical outcomes by amplifying the therapeutic efficiency of routinely prescribed medications. This review delves into the design principles and techniques central to achieving controlled API release using electrospun membranes. The advanced drug release mechanisms of electrospun DDS highlighted in this review illustrate their versatility and potential to improve the efficacy of medical treatments.

show abstract

“…The core-shell needle allowed the polymer in a solvent to inseparably coat an aqueous drug solution as it exited the needle. Wang et al [58] prepared core-shell NFs for DDSs and tissue engineering because they have latent structures that can encapsulate various drugs and achieve tailored release profiles. Here, blends of poly(L-lactide-co-ε-caprolactone) (PLCL) and gelatin were used to electrospin the shell of the core-shell NFs, which could serve as a protective layer for the controlled release behavior of the model drug DOX.…”

Section: Core-shell Nfsmentioning

confidence: 99%

On-Demand Drug Delivery Systems Using Nanofibers

2021

View full text Add to dashboard Cite

On-demand drug-delivery systems using nanofibers are extensively applicable for customized drug release based on target location and timing to achieve the desired therapeutic effects. A nanofiber formulation is typically created for a certain medication and changing the drug may have a significant impact on the release kinetics from the same delivery system. Nanofibers have several distinguishing features and properties, including the ease with which they may be manufactured, the variety of materials appropriate for processing into fibers, a large surface area, and a complex pore structure. Nanofibers with effective drug-loading capabilities, controllable release, and high stability have gained the interest of researchers owing to their potential applications in on-demand drug delivery systems. Based on their composition and drug-release characteristics, we review the numerous types of nanofibers from the most recent accessible studies. Nanofibers are classified based on their mechanism of drug release, as well as their structure and content. To achieve controlled drug release, a suitable polymer, large surface-to-volume ratio, and high porosity of the nanofiber mesh are necessary. The properties of nanofibers for modified drug release are categorized here as protracted, stimulus-activated, and biphasic. Swellable or degradable polymers are commonly utilized to alter drug release. In addition to the polymer used, the process and ambient conditions can have considerable impacts on the release characteristics of the nanofibers. The formulation of nanofibers is highly complicated and depends on many variables; nevertheless, numerous options are available to accomplish the desired nanofiber drug-release characteristics.

show abstract

Doxorubicin hydrochloride‐loaded electrospun poly(l‐lactide‐co‐ε‐caprolactone)/gelatin core–shell nanofibers for controlled drug release

Cited by 9 publications

References 29 publications

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing

Electrospun Nanofibers: Shaping the Future of Controlled and Responsive Drug Delivery

On-Demand Drug Delivery Systems Using Nanofibers

Contact Info

Product

Resources

About